EN DE
STOCK COMPARISON

PT Merry Riana Edukasi Tbk vs Fredun Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how PT Merry Riana Edukasi Tbk (MERI) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: PT Merry Riana Edukasi Tbk trades at IDR 121 versus a fair value of IDR 85 (-30%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
PT Merry Riana Edukasi Tbk
MERI.JK · IDR · Consumer Defensive
-30%
upside to fair value
overvalued
PriceIDR 121
Fair ValueIDR 85
Quality65/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+77%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,155
Quality33/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

PT Merry Riana Edukasi TbkFredun Pharmaceuticals
Valuation
P/E (TTM)42.2×
P/S (TTM)2.23×
P/B5.03×
EV/EBITDA15.5×
Dividend yield0.0%
Dividend per share₹0.70
Profitability
8%Net margin5%
7%Operating margin12%
11%Return on equity16%
6%Return on assets9%
Growth
20%Revenue growth (YoY)27%
Avg. growth/yr (3Y)32.2%
Avg. growth/yr (5Y)36.9%
Balance & size
Debt / equity0.20×
$11MMarket cap$149M
weakGrowth qualityexpensive

Fredun Pharmaceuticals leads: 1 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

PT Merry Riana Edukasi Tbkof which business quality 66 · market factors 10 Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
54
48
Quality GrowthAre margins and returns improving?
19
73
CashflowEarnings quality: real cash, not paper profit
55
5
Fin. StrengthBalance sheet, leverage, solvency risk
100
57
InvestmentDisciplined investing over empire-building
66
16
Low VolatilityCalm price path (market factor)
0
43
MomentumPrice trend over the last 3–12 months (market factor)
20
39
52W MomentumDistance to the 52-week high (market factor)
3
54
Net IssuanceBuybacks instead of dilution
100
7

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

PT Merry Riana Edukasi Tbk

DCF ModelsIDR 114
Earnings-BasedIDR 60
MultiplesIDR 85
Asset-BasedIDR 28
Growth DCFIDR 109
Economic ProfitIDR 64
Growth EarningsIDR 78

18 of 20 models see the stock below the current price.

Fredun Pharmaceuticals

Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535

5 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

PT Merry Riana Edukasi Tbk
Bear IDR 64Fair Value IDR 85Bull IDR 106
IDR 121 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹1,218 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

PT Merry Riana Edukasi Tbk · Consumer Defensive

Quality score65 · Top 25%
Fair value upside-30% · below median

Fredun Pharmaceuticals · Healthcare

Quality score33 · bottom 25%
Fair value upside+77% · Top 25%

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: PT Merry Riana Edukasi Tbk trades at IDR 121 versus a fair value of IDR 85 (-30%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).

PT Merry Riana Edukasi Tbk has the higher quality score (65/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.